Product
Supplier
Encyclopedia
Inquiry
Home > News > Pharma News > J&J Suspends Covid-19 Vaccine Study, Vaccinators Show Unspecified Symptoms

J&J Suspends Covid-19 Vaccine Study, Vaccinators Show Unspecified Symptoms

2020-10-13

Recently, the ongoing Covid-19 vaccine study conducted by Johnson & Johnson has been suspended due to unexplained symptoms in participants.

According to STAT News, a U.S. health and wellness media outlet, the outlet obtained documents sent by Johnson & Johnson to the researchers. The document states that a "moratorium" is in effect and that the online system used to recruit patients has been shut down. In addition, an independent committee tasked with overseeing data and security had met on the 12th.

In a response to the media, Johnson & Johnson confirmed that the study had been suspended due to "unexplained symptoms in one participant" and declined to provide further information. A company statement read: "We must respect the privacy of our participants. We are also now learning about their symptoms and need to clear up all the facts before sharing more information."

However, Johnson & Johnson also stressed that symptoms, accidents and other medical issues could arise in clinical studies. At the same time, the company reiterated that the current moratorium does not amount to a large-scale formal hold, so the public is not being informed. The US media noted that while pauses in clinical studies are not uncommon, vaccine research concerns were significantly higher during the epidemic. Moreover, Johnson & Johnson's study was 60,000 people in size, and a source in the study said that at that size, a new situation could arise even if the issue is resolved this time.

Disclaimer: ECHEMI reserves the right of final explanation and revision for all the information.

Looking for chemical products? Let suppliers reach out to you!

Comment
Comment
  • Life Sciences Industry Overview

    The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.
    Published in: June.2026

Trade Alert

Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)

Scan the QR Code to Share

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.